Skip to main content
Clinical Trials/JPRN-UMIN000034177
JPRN-UMIN000034177
Not yet recruiting
未知

Assessment of functional outcome of elderly patients admitted neurosurgical department-comparison with the frailty before onset. - Assessment of functional outcome of elderly patients admitted neurosurgical department-comparison with the frailty before onset.

Tokyo Women's Medical University Medical Center East0 sites500 target enrollmentOctober 1, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
All neurosurgical disease
Sponsor
Tokyo Women's Medical University Medical Center East
Enrollment
500
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Tokyo Women's Medical University Medical Center East

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Pateints who do not agree with participating this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 1
Survival of elderly patients operated for hip fractureHealth Condition 1: null- proximal femoral fracture.
CTRI/2018/03/012853PGIMER
Completed
Not Applicable
Evaluation of physical function in elderly subjects by botanical extract-formulated food: a randomized, double-blind, placebo-controlled studyot applicable
JPRN-UMIN000033891Maruzen Pharmaceuticals Co., Ltd.34
Recruiting
Not Applicable
Functional outcomes and quality of life of elderly patients with rectal carcinoma
NL-OMON26671Medical Centre Alkmaar80
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.
EUCTR2016-002272-27-BESaarland University388
Active, not recruiting
Phase 1
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2016-002272-27-ATSaarland University388